- call +1-201-465-4211
- email sales@mrinsights.biz
Schizophrenia is a mental disorder characterized by abnormal social behavior and failure to understand reality. Common symptoms include false beliefs, unclear or confused thinking, hearing voices that others do not, reduced social engagement and emotional expression, and a lack of motivation.
Scope of the Report:
This report focuses on the Schizophrenia Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Schizophrenia Drugs is expected to grow at a CAGR of roughly 2.4% over the next five years, will reach 6120 million US$ in 2023, from 5310 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Johnson & Johnson
Bristol-Myers Squibb
Otsuka Pharma
AstraZeneca
Sumitomo Dainippon
Eli Lilly
Alkermes
Vanda Pharma
Allergan
Pfizer
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Oral Antipsychotics
Injectable Antipsychotics
Market Segment by Applications, can be divided into
Hospital
Clinic
There are 15 Chapters to deeply display the global Schizophrenia Drugs market.
Chapter 1, to describe Schizophrenia Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Schizophrenia Drugs, with sales, revenue, and price of Schizophrenia Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Schizophrenia Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Schizophrenia Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Schizophrenia Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Schizophrenia Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Oral Antipsychotics
1.2.2 Injectable Antipsychotics
1.3 Market Analysis by Applications
1.3.1 Hospital
1.3.2 Clinic
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Johnson & Johnson
2.1.1 Business Overview
2.1.2 Schizophrenia Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Johnson & Johnson Schizophrenia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Bristol-Myers Squibb
2.2.1 Business Overview
2.2.2 Schizophrenia Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Bristol-Myers Squibb Schizophrenia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Otsuka Pharma
2.3.1 Business Overview
2.3.2 Schizophrenia Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Otsuka Pharma Schizophrenia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 AstraZeneca
2.4.1 Business Overview
2.4.2 Schizophrenia Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 AstraZeneca Schizophrenia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Sumitomo Dainippon
2.5.1 Business Overview
2.5.2 Schizophrenia Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Sumitomo Dainippon Schizophrenia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Eli Lilly
2.6.1 Business Overview
2.6.2 Schizophrenia Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Eli Lilly Schizophrenia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Alkermes
2.7.1 Business Overview
2.7.2 Schizophrenia Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Alkermes Schizophrenia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Vanda Pharma
2.8.1 Business Overview
2.8.2 Schizophrenia Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Vanda Pharma Schizophrenia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Allergan
2.9.1 Business Overview
2.9.2 Schizophrenia Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Allergan Schizophrenia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Pfizer
2.10.1 Business Overview
2.10.2 Schizophrenia Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Pfizer Schizophrenia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Schizophrenia Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Schizophrenia Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Schizophrenia Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Schizophrenia Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Schizophrenia Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Schizophrenia Drugs Market Analysis by Regions
4.1 Global Schizophrenia Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Schizophrenia Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Schizophrenia Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Schizophrenia Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Schizophrenia Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Schizophrenia Drugs Sales and Growth Rate (2013-2018)
4.5 South America Schizophrenia Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Schizophrenia Drugs Sales and Growth Rate (2013-2018)
5 North America Schizophrenia Drugs by Countries
5.1 North America Schizophrenia Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Schizophrenia Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Schizophrenia Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Schizophrenia Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Schizophrenia Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Schizophrenia Drugs Sales and Growth Rate (2013-2018)
6 Europe Schizophrenia Drugs by Countries
6.1 Europe Schizophrenia Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Schizophrenia Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Schizophrenia Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Schizophrenia Drugs Sales and Growth Rate (2013-2018)
6.3 UK Schizophrenia Drugs Sales and Growth Rate (2013-2018)
6.4 France Schizophrenia Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Schizophrenia Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Schizophrenia Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Schizophrenia Drugs by Countries
7.1 Asia-Pacific Schizophrenia Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Schizophrenia Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Schizophrenia Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Schizophrenia Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Schizophrenia Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Schizophrenia Drugs Sales and Growth Rate (2013-2018)
7.5 India Schizophrenia Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Schizophrenia Drugs Sales and Growth Rate (2013-2018)
8 South America Schizophrenia Drugs by Countries
8.1 South America Schizophrenia Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Schizophrenia Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Schizophrenia Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Schizophrenia Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Schizophrenia Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Schizophrenia Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Schizophrenia Drugs by Countries
9.1 Middle East and Africa Schizophrenia Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Schizophrenia Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Schizophrenia Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Schizophrenia Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Schizophrenia Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Schizophrenia Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Schizophrenia Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Schizophrenia Drugs Sales and Growth Rate (2013-2018)
10 Global Schizophrenia Drugs Market Segment by Type
10.1 Global Schizophrenia Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Schizophrenia Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Schizophrenia Drugs Revenue and Market Share by Type (2013-2018)
10.2 Oral Antipsychotics Sales Growth and Price
10.2.1 Global Oral Antipsychotics Sales Growth (2013-2018)
10.2.2 Global Oral Antipsychotics Price (2013-2018)
10.3 Injectable Antipsychotics Sales Growth and Price
10.3.1 Global Injectable Antipsychotics Sales Growth (2013-2018)
10.3.2 Global Injectable Antipsychotics Price (2013-2018)
11 Global Schizophrenia Drugs Market Segment by Application
11.1 Global Schizophrenia Drugs Sales Market Share by Application (2013-2018)
11.2 Hospital Sales Growth (2013-2018)
11.3 Clinic Sales Growth (2013-2018)
12 Schizophrenia Drugs Market Forecast (2018-2023)
12.1 Global Schizophrenia Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Schizophrenia Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Schizophrenia Drugs Market Forecast (2018-2023)
12.2.2 Europe Schizophrenia Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Schizophrenia Drugs Market Forecast (2018-2023)
12.2.4 South America Schizophrenia Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Schizophrenia Drugs Market Forecast (2018-2023)
12.3 Schizophrenia Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Schizophrenia Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Schizophrenia Drugs Market Share Forecast by Type (2018-2023)
12.4 Schizophrenia Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Schizophrenia Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Schizophrenia Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Schizophrenia Drugs Picture
Table Product Specifications of Schizophrenia Drugs
Figure Global Sales Market Share of Schizophrenia Drugs by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
